Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to bivalent versus quadrivalent HPV vaccination in patients with chronic renal failure
2012-000445-12Phase 4Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Apr 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of human papillomavirus type 16 L1 capsid protein antigen and qHPV vaccine in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Neutralizing HPV-16 and HPV-18 antibody geometric mean titers at day 210. Started Apr 2012; status: terminated.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenqHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on 2012-000445-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000445-12.